Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...
Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in ...
PARIS, FRANCE, 7 May 2025 Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO® (elafibranor) during the European Association for the Study of the ...
Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...
"PBC is one of those liver diseases where you can have cirrhosis and liver failure if you don't do anything about it in a matter of 10 to 15 years," said Lucy Mathew, NP, of Cedars Sinai in Los ...
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo ® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback